Inovio Biomedical (AMEX: INO) is developing a robust pre-clinical and early clinical stage pipeline of innovative DNA-based vaccines and therapeutics that target cancer, influenza, and other infectious diseases (e.g. HIV) based on its SynCon DNA vaccine construct and electroporation DNA delivery technology platforms.